Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Randomized, Double-blind, Placebo-controlled Study to Assess Safety, PK and PD Parameters of CDR132L in Patients With Stable Heart Failure of Ischemic Origin (NYHA 1- 3)

Next Previous
Trial Profile

Phase I, Randomized, Double-blind, Placebo-controlled Study to Assess Safety, PK and PD Parameters of CDR132L in Patients With Stable Heart Failure of Ischemic Origin (NYHA 1- 3)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDR 132L (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; First in man
  • Sponsors Cardior Pharmaceuticals

Most Recent Events

  • 13 Nov 2023 Exploratory Results presented at the American Heart Association Scientific Sessions 2023
  • 13 Nov 2023 Results of post-hoc analysis of pharmacodynamic parameters specifically focused on patients with HFrEF were presented at the American Heart Association Scientific Sessions 2023.
  • 11 Nov 2020 Results published in the European Heart Journal

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top